Introduction
Hypertension is frequently diagnosed in patients with type II diabetes. As a strong independent risk factor, it increases probability of cardiovascular events in this group of patients. There is a lot of hypothesis linking abnormalities in carbohydrate metabolism and in blood pressure regulation; it seems possible that insulin resistance may play an important role. Recently, thiazolidinedions, peroxisome proliferator-activated receptor (PPAR)-g agonists, have been introduced as a new group of drugs for the treatment of type II diabetes. They decrease insulin resistance, but also their protective effect on endothelium and on arterial wall has been demonstrated. 1 Some studies have also documented that PPARs are present in all critical vascular cells: endothelial cells, vascular smooth muscle cells and monocyte-macrophages. 2 These observations suggest that PPARs not only control lipid metabolism but also regulate vascular diseases such as atherosclerosis and hypertension. It has been found that PPAR-g agonists have blood pressure-lowering effects in hypertensive diabetic and nondiabetic patients. 3, 4 There are also reports showing an influence of a mutation in the PPAR-g gene on blood pressure values in humans. 5 Altshuler et al. 6 demonstrated that a common proline-to-alanine substitution at codon 12 (Pro12Ala) of exon B in the PPAR-g gene was associated with protection against type II diabetes, but in some studies an association between the Pro12Ala polymorphism and blood pressure was also found. Douglas and Erdos 7 reported an association between an Ala allele and increased blood pressure values. In type II diabetic patients with body mass index (BMI)440 kg/m 2 and the Pro12Ala variant, diastolic blood pressure was higher than in those with the wild-type variant. In nondiabetic individuals, the Pro12Ala variant was not only associated with higher systolic and diastolic blood pressures but also with higher fasting insulin. However, in another study, Ö stgren et al. 8 showed that the Pro12Ala polymorphism was associated with lower diastolic blood pressure in type II diabetic men, but not in women, where no association was found. The contradictory reports urged us to examine an association between the Pro12Ala polymorphism and blood pressure in obese patients with long-lasting type II diabetes. Until now, all available data were obtained by conventional blood pressure measurements. In order to get more exact insight into blood pressure changes throughout a day, we decided to use ambulatory blood pressure measurement (ABPM).
Patients and methods

Patient selection and clinical investigation
A total of 214 consecutive patients (95 men and 119 women) who had a BMIX30 kg/m 2 and a documented 10-years or longer history of type II diabetes were recruited for the study from a Regional Diabetic Center. The study protocol was approved by the institutional Ethics Committee. All subjects gave informed consent before their enrollment into the study. A detailed interview concerning diagnosis and management of diabetes and hypertension was performed. The data were also collected from the patient medical records. We considered hypertension as diagnosed when either the diagnosis had been present in the medical records or the patient confirmed the diagnosis on interview and was under antihypertensive management. The ABPM recordings were obtained with the use of the SpaceLabs 90207 device (SpaceLabs Inc., Richmond, Washington, USA), validated according to the protocol of the British Hypertension Society. 9 An appropriate largesize cuff was placed on the nondominant arm and blood pressure was registered automatically at 20-min intervals in daytime (0600 to 2200 hours) and at 30-min intervals in night time (2200 to 0600 hours) for a 24-h period. All the patients were instructed to take their antihypertensive medication as usually on the day of the ABPM. For analysis, the ABPM data were cleaned, for example null values were removed, and data were trimmed and edited. Other evaluated parameters included BMI, waist/hip ratio (WHR), glycated haemoglobin A1c in blood (HbA1c, measured by high-pressure liquid chromatography, BIO-RAD), serum glucose (enzymatic method, Cormay), insulin (IRMA, BioSource Europe), triglycerides, total cholesterol and its fractions (enzymatic method, Cobas Integra), microalbuminuria (RIA, ImmunoTech) and serum creatinine (Jaffe method). Diabetic nephropathy was diagnosed in patients with microalbuminuria over 30 mg/day only when the presence of diabetic retinopathy had been confirmed.
Genotyping
The Pro12Ala PPAR-g2 variant was analysed in all the patients by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method described by Ek et al. 10 Genomic DNA was isolated from peripheral blood leukocytes with nonenzymatic and nonorganic method. 11 The following pair of primers was used for DNA amplification by PCR:
as a sense primer (PPAR-f) and 5 0 -AGTGAAGGAATC GCTTTCCG-3 0 as an antisense primer (PPAR-r) (GenBank accession AB005520). These primers yielded PCR product of 236 bp in length. The mismatch (underlined cytosine) near to 3 0 -end of reverse primer was introduced to create a restriction site for HpaII enzyme. The amplicons were incubated at 37 o C for 16 h with 1 U of restriction enzyme HpaII (Fermentas Inc., ON, Canada), and then they were separated by 3% agarose gel electrophoresis stained with ethidium bromide. Results were recorded with photographs of gels in UV light. All samples were independently genotyped on a blind basis in duplicate. The PCR-RFLP results were confirmed by direct sequencing.
Statistical analysis
The software STATISTICA version 6.1. (StatSoft Inc., Tulsa, OK, USA) was used for database management and statistical analysis. Conformity of genotype distribution to Hardy-Weinberg law was assessed using w 2 -test. Fisher's exact test was applied to check significance of differences in nominal variables (gender, hypertension and medication) between genotype groups. Differences in continuous variables between analysed groups of subjects were tested with Mann-Whitney's test. Multivariate analysis was conducted using general linear model. We examined regression between mean blood pressure and BMI values for studied groups, both with and without adjustment for covariates. Coefficients of regression equations were estimated with leastsquare method. P-values were not adjusted for multiple comparisons and Po0.05 was considered statistically significant.
Results
Allele frequencies and differences in characteristics between groups
The distribution of PPAR-g2 genotypes: 154 (72.0%) Pro/Pro, 58 (27.1%) Pro/Ala and 2 (0.9%) Ala/Ala was consistent with Hardy-Weinberg law. The allele frequencies and their 95% confidence intervals (95%CI) were 85.5% (95% CI: 81.9-88.5%) Pro and 14.5% (95% CI: 11.5-18.1%) Ala. For the whole studied group, the distribution of PPAR-g2 genotypes and allele frequencies in our study were similar to previously published data. 6, 7, 10 However, analysis of the Pro12Ala polymorphism gender distribution demonstrated that Ala allele was significantly more frequent in male than in female individuals (P ¼ 0.048) ( Table 1) .
Results of our study were analysed by comparing two subgroups of patients (a) Pro/Pro: homozygotic Pro/Pro and (b) Ala: Ala allele carriers (Ala/ Ala þ Ala/Pro). This way of analysis is justified by a low number of homozygotic Ala/Ala cases, which is consistent with previously reported Pro12Ala variant distribution in other populations. The studied groups were not different when age, diabetes duration, BMI, WHR and diabetes control (HbA 1c ) were compared. We also did not find any difference in the serum glucose and insulin levels as well as lipid metabolism parameters between the groups ( We also compared the antihypertensive medication being used in both studied groups. The most frequently used antihypertensive drugs were angiotensin-converting enzyme (ACE) inhibitors. In Pro/Pro and Ala groups, a similar ratio of patients was treated with ACE inhibitors (69.6 vs 67.8%, respectively; P ¼ 0.87), diuretics (37.2 vs 47.5%; P ¼ 0.21), calcium channel blockers (35.1 vs 34.4%; P ¼ 1.00), b-blockers (23.9 vs 16.4%; P ¼ 0.27) and a-blockers (5.8 vs 3.3%; P ¼ 0.73). We also evaluated proportions of patients taking none, one, two or more antihypertensive drugs in relation to the Pro12Ala polymorphism and we found no difference between the analysed groups (P ¼ 0.93;
Analysis of the ambulatory blood pressure monitoring results Univariate analysis in the population. Univariate analysis of 24-h blood pressure monitoring results revealed significantly higher 24-h and night time diastolic blood pressure in patients with Ala variant. We also observed trends towards higher daytime diastolic blood pressure and 24-h and night time mean arterial pressure (MAP) in patients with Ala variant. There was no difference in 24-h, daytime and night time systolic blood pressure and nocturnal blood pressure fall between the investigated groups ( Table 2) . We also performed a separate analysis for the patients with normal blood pressure (n ¼ 32) and with previously diagnosed hypertension (n ¼ 182). In both subgroups, we did not find a significant difference in 24-h and night time diastolic blood pressure between the Pro/Pro and Ala groups, only a trend towards higher night time diastolic blood pressure as well as 24-h (borderline significant: P ¼ 0.044), daytime and night time MAP in hypertensive patients with Ala variant could be observed (Table 2) .
Analysis in the population with adjustment for gender and other covariates. When all patients were analysed in general linear model with adjustment for gender, Ala variant was still associated with higher 24-h diastolic blood pressure (Po0.05) ( Table 3) , and no significant interaction between genotype and gender was demonstrated. The difference in mean 24-h, daytime and night time diastolic blood pressure between the Pro/Pro and Ala groups remained significant, also after adjustment for age, gender, BMI, serum triglycerides and the presence of diabetic nephropathy (Table 3) . Moreover, the adjustment revealed significant differences in mean 24-h, daytime and night time systolic blood pressure and MAP between the Pro/Pro and Ala groups. Analysis of the subgroup of normotensive patients (n ¼ 32) showed only an association between Ala variant and higher 24-h diastolic blood pressure when the results were adjusted for gender (Table 3) .
Subanalysis in men and women. We also examined whether there was a difference in blood pressure as a function of a PPAR-g genotype in subgroups of women and men analysed separately. We decided to perform such subanalysis in order to relate our results to the previously published report, 8 indicating an influence of gender on genotype-phenotype associations. We found significantly higher night time diastolic blood pressure as well as 24-h and night time MAP in women with the Ala variant than in women with the Pro/Pro genotype. There was also a trend towards higher 24-h, daytime and night time systolic blood pressure and daytime MAP in this subgroup (Table 4 ). In the subgroup of men, we observed no genotype-related difference in blood pressure.
Analysis of an interaction between genotype, body mass index and ambulatory blood pressure monitoring results. Although no correlation between BMI and mean 24-h diastolic blood pressure in the studied groups was found (Pearson's linear correlation coefficient R ¼ þ 0.06, P ¼ 0.43), a significant interaction between Pro12Ala polymorphism and BMI in their influence on diastolic blood pressure was demonstrated. When no adjustment for covariates was made, Ala variant was associated with more steep ascending slope of a line representing the regression between BMI and 24-h diastolic blood pressure as evidenced by significant difference (P ¼ 0.01) between coefficients in the regression equations for the groups Pro/Pro and Ala (À0.091 and þ 0.449, respectively, Figure 1 ). The same finding concerned daytime and night time diastolic blood pressure (the regression equations for the groups Pro/Pro and Ala, respectively: for daytime diastolic blood pressure: À0.084 and þ 0.427, P ¼ 0.023; for night time diastolic blood pressure: À0.102 and þ 0.500, P ¼ 0.0063). Similar significant (Po0.05) differences between the slopes of regression lines for the genotype groups were observed when the models were adjusted for covariates sex, age, triglycerides and the presence of diabetic nephropathy.
Discussion
The most important finding in our study is that in obese individuals with type II diabetes, there is an association between the Pro12Ala PPAR-g2 variant and mean 24-h and night time diastolic blood pressure. The results are consistent with a study by Douglas et al. 7 who demonstrated substantially higher diastolic blood pressure in severely obese diabetic patients with the Ala allele. However, Douglas et al. 7 evaluated blood pressure by calculating a mean of two measurements obtained with the use of a classical method, not of an ABPM. In members of families with a strong history of type II diabetes and with the Pro12Ala variant, Hasstedt et al. 12 found that both systolic and diastolic blood pressures were elevated compared to individuals with the wild-type ProPro variant. Also in that study, the difference for diastolic blood pressure was more significant than for systolic pressure. All the results are in opposition to a study of Ö stgren et al. 8 who showed that the Pro12Ala variant was associated with lower diastolic blood pressure in type II diabetic men, but not in women, where no association was found. One of the explanation for this discrepancy may be the use of different antihypertensive medications by many of the analysed patients. In the study of Ö stgren et al., 8 about 50% of studied subjects suffered from arterial hypertension. Unfortunately, the authors gave no exact data on differences in antihypertensive treatment between the patients with different genotypes, but b-blockers and diuretics were the most frequently used. In our study, arterial hypertension was diagnosed in over 80% of the individuals studied and there was no difference in the prevalence of hypertension related to the PPAR-g genotype. We also compared the antihypertensive medication being used in both studied groups. The most frequently used antihypertensive drugs were ACE inhibitors, but a similar ratio of patients from both groups were treated with ACE inhibitors, diuretics, calcium channel blockers, b-blockers and a-blockers. As the antihypertensive therapy is a major confounding factor in our study, we performed a separate analysis of ABPM results in a subgroup of normotensive patients (i.e. without any antihypertensive medication). The univariate analysis did not reveal any association between the Pro12Ala variant and blood pressure, only when the results were adjusted for gender, and mean 24-h diastolic blood pressure was significantly higher in the patients with Ala variant. The small number of normotensive patients in our study (only 32 individuals) is a huge limitation for drawing any conclusion from the analysis of this subgroup. However, also in the separate analysis of ABPM results in hypertensive patients only, we did not find a significant association between the Pro12Ala genotype and diastolic blood pressure. It might suggest that ABPM results obtained in normotensive patients could have had some positive impact on the finding of the genotype-phenotype association in the whole analysed group, but it could also be just an effect of a higher number of individuals in the whole study group.
Despite arguments for the association between the Pro12Ala polymorphism of the PPAR-g2 gene and higher blood pressure, it is not the only possible explanation of our results. It cannot be excluded that in patients with the Pro12Ala variant, ACE inhibitors are simply less effective owing to an unknown interaction between the PPAR-g gene and the reninangiotensin system. There is an increasing number of reports suggesting such a link. Sugawara et al. 13 showed that stimulation of PPAR-g leads to suppression of type 1 angiotensin II receptor gene expression in rat vascular smooth muscle cells. The authors suggest that PPAR-g ligands may inhibit AII-induced cell growth and hypertrophy in VSMCs by suppressing AT1R expression and might be beneficial for treatment of diabetic patients to avoid cardiovascular complications. It has also been demonstrated recently that the PPAR-g activators rosiglitazone and pioglitazone prevent hypertension in Ang II-infused rats and abrogate structural, functional, and molecular changes induced by Ang II in blood vessels by exerting direct effects on the vascular wall, leading to inhibition of cell growth and inflammation. 14 The association of the Pro12Ala variant and higher diastolic blood pressure might be related to the fact that the polymorphism results in reduced function of the PPAR-g. It has been shown that the Pro12Ala substitution in PPAR-g gene lowers affinity of PPAR-g2 for binding to PPAR response element. 15 As thiazolidinediones, PPAR-g agonists, have been shown to decrease blood pressure in both diabetic 4 and nondiabetic individuals, 3 the hypothesis that reduced PPAR-g function results in blood pressure increase is even more plausible. Wu et al. 16 demonstrated that in adult spontaneously hypertensive rats (SHR), vascular PPAR-g protein expression was significantly decreased in comparison with the age-matched Wistar-Kyoto rats (WKY) and systolic blood pressure in SHR was significantly higher than in WKY. Chronic rosiglitazone treatment retarded hypertension development in SHR. The consequence of the reduced function of the PPAR-g in individuals with the Pro12Ala polymorphism would be a weaker response to PPAR-g stimulation. One may speculate that in patients with the Pro12Ala variant, the blood pressure-lowering effect of PPAR-g stimulation would be weaker than in subjects with the wild-type Pro/Pro variant. However, we are not aware of any study examining an influence of thiazolidinediones on blood pressure as a function of a PPAR-g gene polymorphism.
In our study the significantly higher blood pressure values in individuals with the Pro12Ala polymorphism were found in diastolic blood pressure only, but the same trends were observed for 24-h and night time MAP. After adjustment for gender, age, triglycerides, BMI and diabetic nephropathy, we found that the genotype-related differences were significant for 24-h, daytime and night time systolic and diastolic blood pressures and MAP. However, the differences were small and of borderline statistical significance. Considering the presence of confounding factors, like various antihypertensive and antidiabetic treatment, one must be careful with interpretation of the results. If the association between the Pro12Ala variant and higher blood pressure exists, it is rather weak and much higher number of individuals would have to be examined to obtain more significant differences.
Another interesting issue is that our results suggest an influence of the Pro12Ala polymorphism on correlation between BMI and diastolic blood pressure. A positive relationship of BMI to blood pressure in normal and in diabetic individuals is well documented. [17] [18] [19] PPAR-g genotype might modify the correlation between BMI and diastolic blood pressure in such a way that in the presence of the Pro12Ala variant, diastolic blood pressure increases more in parallel to BMI increase than in individuals with the wild-type genotype. It is also possible that diastolic blood pressure increase is related to the presence of Pro12Ala variant, which becomes more prominent when BMI increases. In any case, it might suggest that Pro12Ala polymorphism analysis would help in prediction in which individuals body weight change results in greater diastolic blood pressure changes. In our study we also found significantly higher prevalence of hypertension in severely obese (BMIX35 kg/m 2 ) subjects in comparison to subjects with BMIo35 kg/m 2 for patients with Ala variant, but no such relationship was observed for the Pro/Pro genotype. This is another argument supporting hypothesis of the interaction between Pro12Ala polymorphism and BMI in their influence on blood pressure.
We also examined if there was a gender-related difference in blood pressure as a function of the Pro12Ala polymorphism. We found significantly higher mean night time diastolic blood pressure as well as mean 24-h and night time MAP in women with the Ala variant and no genotype-related difference in blood pressure in men. It is different from the results reported by Ö stgren et al. 8 where men with the Ala allele had lower systolic blood pressure than men with the Pro/Pro variant. Any other study analysing an association between the Pro12Ala polymorphism and blood pressure did not suggest any gender-related difference. 7, 12, 20 Also in our study when all patients were analysed in general linear model with adjustment for gender, Ala variant was still associated with higher mean 24-h diastolic blood pressure (Po0.05), and no significant interaction between genotype and gender was demonstrated. It may suggest that the gender-related differences in association between the Pro12Ala polymorphism and blood pressure in our study are rather a statistical bias than a reflection of a real association.
Our results also indicate that in the population studied, the Ala allele was significantly more frequent in male than in female candidates. Such a finding would have important implications, considering the fact that the risk of developing type II diabetes in Pro allele carriers is 1.25-fold higher than in Ala allele carriers. 6 Results of our study might suggest that male individuals are less protected from type II diabetes by the presence of the Ala allele in this particular population. However, owing to a lack of a control group of healthy individuals, we are unable to give an appropriate interpretation of this finding. Moreover, the difference found in our study is of weak statistical significance. As we did not expect such a result and there are no similar data on a gender-related differences in genotype distribution in publications concerning the Pro12Ala polymorphism, it is more probable that our finding is rather accidental.
In conclusion, to our knowledge we are the first to demonstrate an association between the Pro12Ala PPAR-g2 variant and increased 24-h and night time diastolic blood pressure in obese, type II diabetic patients. Our findings go along with outcomes of some previous studies with the use of conventional blood pressure measurement. 7, 12 However, it must be stressed that most of the patients in our study was under antihypertensive medication, which is a strong confounding factor. Our results also suggest that in type II diabetes, diastolic blood pressure increases more in parallel to BMI increase in the patients with the Pro12Ala variant in comparison to those with the wild-type Pro/Pro variant.
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What is known on this topic? K Peroxisome proliferator-activated receptor gamma seem to play an important role in the modulation of mechanisms responsible for development of insulin resistance. There are also observations suggesting that PPAR-g are involved in a blood pressure regulation. For obese patients with type II diabetes who usually are both insulin resistant and hypertensive, full knowledge on PPAR-g biology is of particular importance. In some studies, an association between the Pro12Ala polymorphism of the PPAR-g2 gene and blood pressure was found; however, opposite results have also been reported. So far in all the studies, blood pressure was measured by a conventional method.
What this study adds?
K This is the first study that demonstrates an association between the Pro12Ala variant of the PPAR-g2 gene and increased 24-h and night time diastolic blood pressure in obese, type II diabetic patients. It might confirm some previous findings in patients with type II diabetes with the use of conventional blood pressure measurement.
